Financial Highlights - Total contract revenues increased by 14.1% year-over-year, from $1.272 billion in Q3 2025 to $1.4518 billion in Q3 2026[6] - Organic revenue growth was 7.2%[6] - Adjusted EBITDA increased by 28.5% year-over-year, from $170.7 million in Q3 2025 to $219.4 million in Q3 2026[6] - Adjusted EBITDA margin improved by 169 basis points, from 13.4% in Q3 2025 to 15.1% in Q3 2026[6] - Adjusted diluted EPS increased by 35.4% year-over-year, from $2.68 in Q3 2025 to $3.63 in Q3 2026[6] Backlog and Debt - Total backlog increased by 4.7% year-over-year[16] - Next 12 Months Backlog increased 11.8% year-over-year[16] - The company executed additional service and maintenance agreements totaling over $500 million subsequent to the quarter[16] - Total notional amount of debt was $945 million in Q3 2026, compared to $1.035 billion in Q2 2026[17] Power Solutions Acquisition - Dycom is set to acquire Power Solutions for a total purchase price of $1.95 billion[36] - Power Solutions' annual revenue is expected to be approximately $1.0 billion for CY2025, with a 4-year revenue CAGR of approximately 15%[36] - Power Solutions has consistently delivered Adjusted EBITDA margins in the mid-to-high teens, which is expected to be sustained in CY2026[36] Fiscal 2026 Outlook - The company is increasing the midpoint of its revenue guidance and now expects total contract revenues for fiscal 2026 to range from $5.350 billion to $5.425 billion, representing a range of 13.8% to 15.4% total growth over the prior year[22]

InTest Corporation 17th Annual Southwest Ideas Conference November 19, 2025 Nick Grant, President and CEO Duncan Gilmour, CFO and Treasurer NYSE American: INTT | NYSE American: INTT | Forward-looking Statements and Key Performance Metrics Forward-Looking Statements This presentation includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. These statements do not convey historical information but relate to predicted or potential future events ...

Copyright © 2025 Griffon Corporation. All rights reserved. Q4 FY25 INVESTOR PRESENTATION November 2025 GRIFFON OVERVIEW B R E A K D O W N B Y O P E R A T I N G S E G M E N T $2.5B $522M $3.2B 21% $1.3B 5,111 Revenue Adj. EBITDA Market Cap1 Adj. EBITDA Net debt2 CPP 37% 1. Closing price of $69.7/share on 11/14/2025 and 46,231,089 shares outstanding as of 10/31/25. 2. Net debt is defined as long-term debt less cash per Griffon's balance sheet Adjusted EBITDA (excl. unallocated) $millions) Revenue U.S. 81% Int ...

Financial Performance - Total registered users are approximately 299 million[11] - Q3'25 transaction revenue reached $65 million, a 20% year-over-year increase[11] - Q3'25 partners revenue was $192 million, up 24% year-over-year[11] - Creative Subscriptions Annualized Recurring Revenue (ARR) is approximately $1.5 billion[11] - Q3'25 free cash flow (FCF) margin was 32%[11] - Q3'25 gross payment volume (GPV) reached $3.7 billion, a 13% year-over-year increase[11] Revenue and Bookings - Total revenue for 2025 is estimated to be between $1.99 billion and $2 billion[23] - Creative Subscriptions ARR expanded consistently, reaching $1.457 billion in Q3'25, an 11% year-over-year increase[27] - Total bookings for 2025 are projected to be between $2.06 billion and $2.078 billion[30] Strategic Initiatives - Base44, acquired in June 2025, is projected to generate at least $50 million of ARR by the end of 2025[19] - The Q1'25 user cohort is the strongest since the COVID cohort, growing 8% year-over-year and 17% quarter-over-quarter[39] - The company expects approximately $18.4 billion in future bookings over the next 10 years from existing cohorts[46]

TARA-002 in Lymphatic Malformations (LMs) - LMs represent a significant pediatric rare disease opportunity with no currently approved therapies[8] - TARA-002 has the potential to treat macrocystic and mixed cystic LMs, which most often are present in the head and neck region[11] - The incidence of LMs is approximately 1,400-1,800 cases per year, with a prevalence of approximately 20,000 patients seeking treatment[14] - Macrocystic LMs account for approximately 47%, microcystic LMs for approximately 21%, and mixed LMs for approximately 32% of cases[14] STARBORN-1 Interim Data - In the STARBORN-1 trial, TARA-002 demonstrated clinical success in 80% of patients that completed treatment[30] - Among evaluable patients in STARBORN-1, TARA-002 showed a 100% clinical success rate at 8-weeks post-treatment[30] - In evaluable patients, 83% with macrocystic LMs, 100% with mixed-cystic LMs and 100% with Ranula achieved complete or substantial response[35] - In the STARBORN-1 trial, 66.7% of patients experienced any grade TEAEs, with 8.3% experiencing Grade 3 TEAEs and no Grade 4/5 TEAEs[39] OK-432 Data Review - OK-432, the predecessor compound to TARA-002, has shown strong safety and efficacy results in over 500 U S pediatric LMs patients in a University of Iowa-led study[18] - OK-432 demonstrated a 69% clinical success rate in the immediate treatment group 6 months after enrollment[46] - OK-432 showed an 84% clinical success rate in patients with macrocystic lesion types[46]

Market Overview and Growth - Nokia's addressable market in 2028 is estimated to be €72 billion for Telecommunication Providers, €24 billion for AI & Cloud, and €20 billion for Mission Critical Enterprise including Defense[20] - The market CAGR from 2025 to 2028 is projected at 1% for Telecommunication Providers, 16% for AI & Cloud, and 11% for Mission Critical Enterprise including Defense[20] - Consumer AI traffic is expected to grow at a CAGR of over 20% over the next decade, while enterprise and industrial AI traffic is projected to grow at approximately 50% CAGR over the same period[11, 12] - Network Infrastructure's serviceable addressable market (SAM) is expected to grow from €48 billion in 2025 to €60 billion in 2028, representing a 9% CAGR[16, 74] Financial Performance and Targets - Network Infrastructure achieved 8% net sales growth (TTM Q4'24-Q3'25) and aims for a 6-8% CAGR from 2025-2028[29] - Network Infrastructure targets an operating margin of 13%-17% by 2028, compared to the current 10% (TTM Q4'24-Q3'25)[29] - Mobile Infrastructure aims to increase its operating profit from a base of €15 billion and achieve a gross margin of 48-50% by 2028[29] - The company is targeting a reduction in the corporate center cost base to €150 million, from the current €360 million (TTM Q4'24-Q3'25)[29] - Nokia is targeting a double-digit CAGR comparable operating profit growth through 2028[32, 183] Strategic Priorities and Portfolio Management - Nokia is divesting from portfolio businesses with €09 billion TTM revenue and €-01 billion TTM operating margin[26] - Technology Standards has over €08 billion of annual revenue under contract until 2030 and over €02 billion of annual revenue run-rate from expansion areas[153, 158]

Net sales were 1.5% lower than 2024, and comparable sales declined 2.7%. Bottom line results Home / News & Features COMPANY Q3 2025 Results and Positioning Target for Its Next Chapter of Growth Nov 19, 2025| 5-minute read Copy link to share C- This morning, Target announced our third quarter 2025 earnings. Check out the full results and read on for a snapshot. Q3 2025 results were in line with our expectations Topline sales Adjusted EPS* of $1.78 was about 4% lower than last year, and GAAP EPS was $1.51. Gr ...

RISE UP Phase 3 Trial Results - Mitapivat met the primary endpoint with a 40.6% hemoglobin response rate, defined as ≥1.0 g/dL increase in average Hb from Week 24 through Week 52 compared to baseline, significantly higher than the 2.9% in the placebo arm[38] - There was a trend favoring mitapivat with a 14% reduction in the annualized rate of sickle cell pain crises (SCPCs) compared to placebo, although this did not reach statistical significance[39] - Mitapivat showed a statistically significant improvement in average change from baseline in hemoglobin concentration, with a 7.43 g/L difference compared to placebo[41] - Mitapivat significantly reduced the average change from baseline in indirect bilirubin compared to placebo, with a difference of -16.91 µmol/L[46] - The trial showed a trend in favor of mitapivat with a 14% reduction in the annualized rate of hospitalizations for SCPC compared to placebo[50] - Percent reticulocytes substantially decreased from baseline in the mitapivat arm vs placebo[52] Safety and Discontinuation - The safety profile observed in the RISE UP Phase 3 trial was consistent with previous mitapivat sickle cell disease trials, with no new safety signals identified[57] - The discontinuation rate in the double-blind treatment period was low, with 13% in the mitapivat arm and 18.8% in the placebo arm[34] Next Steps - The company intends to submit a marketing application for mitapivat in the U S for sickle cell disease after a pre-sNDA meeting with the FDA in Q1 2026[61, 68]

Q3 2025 Business Update - Net Yield increased by 7.1% year-over-year[10] - 2025 Advance Bookings reached 96% of Capacity PCD sold[10] - 2026 Advance Bookings reached 70% of Capacity PCD sold[10] Q3 2025 Financial Highlights - Total revenue for the three months ended September 30, 2025, was $2 billion, compared to $1.679 billion in 2024[28] - Adjusted Gross Margin for the three months ended September 30, 2025, was $1.334 billion, compared to $1.099 billion in 2024[28] - Net income for the three months ended September 30, 2025, was $514 million, compared to $380 million in 2024[28] - Adjusted EBITDA for the three months ended September 30, 2025, was $704 million, compared to $554 million in 2024[28] - Adjusted EBITDA Margin was 52.8% for the three months ended September 30, 2025, compared to 50.4% in 2024[28] Viking River and Viking Ocean Key Metrics (Nine Months Ended September 30, 2025) - Consolidated Occupancy was 95.5%[30] - Consolidated Adjusted Gross Margin was $3.184 billion[30] - Consolidated Net Yield was $598[30] Strong Cash Generation and Manageable Bond Maturities - Cash and cash equivalents as of September 30, 2025, were $3 billion[37] - Net Debt as of September 30, 2025, was $2.8 billion[37] - Net Leverage was 1.6x as of September 30, 2025[37] Business Outlook - 2025 Season Advance Bookings reached $5.6 billion, a 21% growth, with 96% Capacity PCD sold[42] - 2026 Season Advance Bookings reached $4.9 billion, a 14% growth, with 70% Capacity PCD sold[44]

3Q25 Earnings Call 19 November 2025 NASDAQ: GDS HKEX: 9698 0 © GDS 2016 DISCLAIMER This presentation contains forward-looking statements within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and as defined in the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as "may," "will," "expect," "anticipate," "aim," "estimate," "intend," "plan," "believe," "potential," "continue," "is/are likely to" or othe ...